Business · 06/11/20261 min read
Combinations of iOnctura's roginolisib revert immune suppression in immunotherapy-resistant NSCLC
Summary
Late breaking data from ongoing Phase I/II PULMO-01, the first clinical study of conformation-selective PI3Kδ inhibitor roginolisib in immunotherapy-resistant non-small cell lung cancer (NSCLC), presented at SITC…
Original source language: PR Newswire UK — News ReleasesOpen original release →